Rigel Pharmaceuticals, Inc. (RIGL:NASDAQ) closed at $44.46 on November 13, 2026, down 2.69% on the day. The stock trades 15.5% below its 52-week high of $52.61 and 78.2% above its 52-week low of $24.95. Over the past year, it gained 6.0%. Rigel Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, RIGL closed higher on 131 days (52%). Its best day was May 12, 2026 (+12.10%) and its worst was November 6, 2026 (-13.26%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 2 times.
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisc...
Find more stocks like RIGL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.